Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Skyrizi
| Field | Information |
|---|---|
| Medication Name | Skyrizi |
| Generic Name | Risankizumab-rzaa |
| Purpose | Treatment of moderate to severe plaque psoriasis and psoriatic arthritis in adults. Also used to treat Crohn’s Disease. |
| Mechanism of Action | Selective interleukin-23 (IL-23) inhibitor; binds to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor. |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 150 mg/mL |
| Dosage Frequency | Initially, two subcutaneous injections at Week 0, Week 4, and then every 12 weeks thereafter. |
| Common Side Effects | Upper respiratory infections, injection site reactions, fungal skin infections, fatigue, headache. |
| Serious Side Effects | Serious allergic reactions, infections (e.g., tuberculosis), inflammatory bowel disease. |
| Drug Interactions | Live vaccines, other immunosuppressants. |
| Important Notes | Inform your doctor of any infections or history of tuberculosis before starting Skyrizi. Avoid live vaccines during treatment. |
| Storage | Store in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately for guidance. Do not administer an extra dose without consulting your doctor. |
| Alternatives | Humira (adalimumab), Stelara (ustekinumab), Taltz (ixekizumab), Cosentyx (secukinumab) |
Skyrizi Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Humira (adalimumab) | TNF-alpha inhibitor | Used for psoriasis and psoriatic arthritis. |
| Stelara (ustekinumab) | IL-12 and IL-23 inhibitor | Used for psoriasis and psoriatic arthritis. |
| Taltz (ixekizumab) | IL-17A inhibitor | Used for psoriasis and psoriatic arthritis. |
| Cosentyx (secukinumab) | IL-17A inhibitor | Used for psoriasis and psoriatic arthritis. |
Skyrizi Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Upper respiratory infections | Serious allergic reactions |
| Injection site reactions | Infections (e.g., tuberculosis) |
| Fungal skin infections | Inflammatory bowel disease |
| Fatigue | Worsening of Crohn’s Disease |
| Headache | Liver problems |
Skyrizi Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Plaque Psoriasis | 150 mg | 150 mg every 12 weeks after initial doses at Week 0 and Week 4. | Subcutaneous injection. Rotate injection sites. |
| Psoriatic Arthritis | 150 mg | 150 mg every 12 weeks after initial doses at Week 0 and Week 4. | Subcutaneous injection. Rotate injection sites. |
| Crohn’s Disease | 300 mg | 150 mg every 8 weeks after initial doses | Subcutaneous injection. Rotate injection sites |
Skyrizi Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $25 |
| Without Insurance (U.S.) | $20,000 |
| From CPS | $7235 |
